The Democratic Republic of the Congo's government reported 3,200 Ebola infections and at least 1,405 deaths as of July 27, 2026, marking a surge of approximately 1,000 cases in just ten days and deepening what has become one of the most rapidly accelerating Ebola outbreaks in the country's history Al Jazeera.

The outbreak, officially declared on May 15, 2026, is caused by the Bundibugyo strain of the Ebola virus. Unlike the Zaire ebolavirus strain responsible for prior DRC epidemics, Bundibugyo has no approved vaccine or therapeutic. Several candidate vaccines are being fast-tracked for clinical trials, and two potential treatments are under development, but neither is available for deployment at scale. On July 24, 2026, Oxford University announced that the first volunteer group had received an experimental vaccine targeting the Bundibugyo strain Al Jazeera.

The trajectory of the outbreak has been steep. The CDC, reporting data through July 22, 2026, documented 2,905 confirmed cases and 1,269 deaths, with zero probable cases or deaths remaining CDC. The CDC also noted that the 2026 outbreak surpassed 1,000 confirmed cases within 40 days of response activation. Ten days earlier, the WHO's Disease Outbreak News item 613, published July 17, recorded 2,124 confirmed cases and 828 deaths as of July 15, with a crude case fatality ratio of 39 percent WHO. On June 7, Reuters reported just 515 confirmed cases Reuters. The curve has not flattened.

The WHO has stated that nearly 90 percent of cases are concentrated in Ituri Province, which borders South Sudan and Uganda. The virus is now confirmed in five provinces, including two where it has spread recently Al Jazeera. Cross-border transmission has already occurred: Uganda confirmed five cases by May 23 Reuters, and the WHO declared the outbreak a Public Health Emergency of International Concern on May 17, covering both the DRC and Uganda WHO.

The PHEIC declaration came just two days after the DRC's outbreak was formally declared, when confirmed cases in Ituri still numbered in the single digits. As of May 16, the WHO had recorded eight laboratory-confirmed cases, 246 suspected cases, and 80 suspected deaths in Ituri. The escalation from those figures to 3,200 confirmed infections in roughly ten weeks reflects a reproduction rate that has outpaced every prior DRC Bundibugyo outbreak on record.

Operational constraints are compounding the epidemiological challenge. Healthcare workers in the DRC have been striking over unpaid wages, disrupting Ebola response efforts in some hospitals. The UN Humanitarian Air Service is flying medics, response teams, and lab samples to front-line areas, maintaining a logistical lifeline in regions where overland transport is unreliable or nonexistent Al Jazeera. On July 16, Reuters reported that the US government moved to block Americans in the DRC from immediate travel home, citing the outbreak Reuters.

The broader context here matters for assessing what comes next. Ebola has killed more than 15,000 people across Africa over the past 50 years, but those fatalities were overwhelmingly caused by the Zaire and Sudan strains, both of which now have either licensed vaccines or candidate countermeasures at advanced clinical stages. The Bundibugyo strain, first identified in Uganda in 2007, has historically produced smaller outbreaks with lower case counts. The DRC's 17th Ebola outbreak is now rewriting that epidemiological profile. The absence of a licensed vaccine means that ring vaccination, the cornerstone of the Zaire-strain response playbook, is not available as a containment tool. Contact tracing, isolation, and infection prevention and control at health facilities remain the primary instruments, and they are being implemented in a setting where frontline health workers are unpaid and where conflict-affected provinces complicate surveillance access.

The geographic vector is equally consequential. Ituri Province shares a porous border with South Sudan and Uganda. The WHO's confirmation of spread into two new provinces raises the prospect of the outbreak establishing itself in population centers farther from the current epicenter, potentially overwhelming surveillance capacity in regions with limited health infrastructure. South Sudan, in particular, operates a fragile health system under chronic humanitarian strain.

Several variables will shape the coming weeks. The Oxford vaccine trial is in its earliest phase, with no timeline for efficacy data or potential emergency use authorization. The two therapeutics under development for the Bundibugyo strain are similarly pre-deployment. Until a biomedical tool reaches the field, the response depends entirely on conventional public health measures operating under severe constraints. The speed of the last ten days, in which the case count grew by roughly 1,000, suggests that current containment efforts are not keeping pace with transmission. Whether that trajectory stabilizes will depend on factors that are operational rather than scientific: the resolution of healthcare worker strikes, the reach of contact-tracing teams into newly affected provinces, and the capacity of neighboring surveillance systems to detect cross-border cases before they seed secondary chains.